Capstone Investment Advisors
SUPN icon

Capstone Investment Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Capstone Investment Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Buy
6,902
+1,404
+26% +$67.4K ﹤0.01% 1421
2026
Q1 		$284K Sell
5,498
-3,356
-38% -$171K ﹤0.01% 1386
2025
Q4 		$440K Buy
+8,854
New +$431K ﹤0.01% 1191

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Capstone Investment Advisors's SUPN Position: Q2 2026 in Review

Capstone Investment Advisors increased its Supernus Pharmaceuticals (SUPN) stake by 26% in Q2 2026, buying an estimated $67.4K and bringing the position to 6,902 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #1421.

Capstone Investment Advisors first reported a position in SUPN in Q4 2025 and has held it in 3 quarters since. The position peaked at $440K in Q4 2025. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Capstone Investment Advisors held 6,902 shares of Supernus Pharmaceuticals worth $321K as of Q2 2026.
  • Capstone Investment Advisors bought 1,404 Supernus Pharmaceuticals shares in Q2 2026, an estimated $67.4K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1421 holding.
  • Capstone Investment Advisors first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Capstone Investment Advisors's Supernus Pharmaceuticals position peaked at $440K in Q4 2025.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.